EyePoint, Inc. (EYPT)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Ophthalmologysrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
MEDIUM DILUTION RISKDilution score: 43/100 (MEDIUM), 11.9 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 27.62% of float, squeeze risk: HIGH
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- EyePoint (EYPT) Stock Sees Fair Value Cut After Split Analyst Revisions On LUGANO
- EyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meeting
- EyePoint Faces Regulatory Uncertainty After Lugano Trial Miss, RBC Capital Markets Says
- EyePoint’s Duravyu falls short to Eylea in Phase III trial
- EyePoint’s Regulatory Overhang May Take Time To Clear After Wet AMD Trial Setback, RBC Says – Retail Calls EYPT Slump A ‘Huge Overreaction’
- EyePoint (EYPT) LUGANO Data Resets The Story, Is It A Bargain?
- Why Did EYPT, STLA, ENVX Stocks Plunge To 52-Week Lows Today?
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for EyePoint, Inc..
Full EYPT Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.